对参数性侵袭的预测因子的探索以及它如何影响大容量宫癌的治疗策略
Jing Yang1, Jianan Ji1, Xiao Ni1
1Department of Gynecology, First Affiliated Hospital with Nanjing Medical University, Nanjing, China.
Frontiers in oncology
|October 16, 2025
概括
庞大的宫癌 (BCC) 患者具有先进的FIGO阶段或大型瘤容易发生参数入侵 (PMI). 彻底手术和辅助放射治疗 (RS和ART) 改善了没有PMI的早期BCC的无进展生存期 (PFS).
科学领域:
- 妇科瘤学 妇科瘤学
- 辐射瘤学 辐射瘤学
- 手术瘤学手术瘤学
背景情况:
- 宫癌的治疗,特别是对于重的疾病,在局部控制和转移方面面临挑战.
- 参向性侵袭 (PMI) 是影响大癌 (BCC) 结果的关键因素.
研究的目的:
- 为了确定在庞大的宫癌 (BCC) 中参数性侵袭 (PMI) 的预测因素.
- 评估不同治疗方式对BCC患者与没有PMI的生存结果的影响.
主要方法:
- 在2010年1月至2023年6月期间接受治疗的462名BCC患者的回顾性分析.
- 用于PMI预测分析的逻辑回归; 用于生存分析的Kaplan-Meier和Cox回归.
主要成果:
- FIGO III-IV 阶段和瘤体积> 16 cm3 独立预测PMI.
- PMI与较差的无进展生存率 (PFS) 相关,但与癌症特异性生存率 (CSS) 无关.
- 对于没有PMI的FIGOI-II阶段BCC,激进手术和辅助放射治疗 (RS和ART) 与并发化学放射治疗 (CCRT) 相比,改善了PFS,CSS或不良事件没有显著差异.
结论:
- 先进的FIGO阶段和较大的瘤体积是BCC中PMI的关键风险因素.
- RS和ART为选择没有PMI的早期BCC患者提供了改善的PFS,保持生活质量和安全.
更多相关视频
相关概念视频
02:18Cancer
Cancers arise due to mutations in genes involved in the regulation of cell division, which leads to unrestricted cell proliferation. Modern science and medicine have made great strides in the understanding and treatment of cancer, including eradicating cancer in some patients. However, there is still no cure for cancer. This is largely due to the fact that cancer is a large group of many diseases.
02:49Cancer Therapies
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
02:50Combination Therapies and Personalized Medicine
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
02:56Treatment Resistent Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
01:21Cancer Survival Analysis
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...